Showing results (51-60 of 312) with videos related to
Sort By:
Pageof 32
The Canadian Journal of Urology|November 15, 2002
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guidelineRoanne Segal, Eric Winquist, Himu Lukka, et al.Investigational New Drugs|July 22, 2005
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinomaPhilip E Shaheen, Walter Stadler, Paul Elson, et al.American Journal of Clinical Oncology|February 8, 2006
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancerAnna Tinker, Eric Winquist, Christina Canil, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 27, 2019
Early experience with chemotherapy intensification for poor-prognosis metastatic germ cell cancer and unfavorable tumor marker declineAnupam Batra, Scott Ernst, Kylea Potvin, et al.Breast Cancer Research and Treatment|April 19, 2014
Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22Simon D Baxter, Wendy A Teft, Yun-Hee Choi, et al.Clinical Nuclear Medicine|June 11, 2020
Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CTKatherine A Zukotynski, Hossein Jadvar, Kylea Potvin, et al.Urologic Oncology|May 24, 2005
A Phase II study of oxaliplatin in urothelial cancerEric Winquist, Everett Vokes, Malcolm J Moore, et al.The Journal of Urology|June 17, 2008
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi, Joseph L Chin, Eric Winquist, et al.Investigational New Drugs|March 30, 2007
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Jennifer J Knox, Sebastien J Hotte, Christian Kollmannsberger, et al.Journal of Oncology Practice|September 4, 2012
Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agentsMatthew A Weir, Tara Gomes, Eric Winquist, et al.Pageof 32